Inspection Record

OPS International Incorporated D/B/A Olympia Pharmacy — FDA 483 Findings

US FDAInspected 2018-05-30Published 2024-01-17 9 findingsContamination controlLabeling and packagingQuality unit oversightRegulatory reporting and change controlAseptic processing and sterility assuranceLaboratory and QC controls

View the regulator's official source The source document is always the basis for judgement.

Findings

1Contamination control

Protective apparel is not worn as necessary to protect drng products from contamination.

2Labeling and packaging

Product Labeling: The labels of some of your outsourcing facility's drug products do not include information required by section 503B(a)(10)(A).

3Quality unit oversight

The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.

4Regulatory reporting and change control

Product Reporting: Your outsourcing facility has not subinitted a report to FDA identifying a product compounded during the previous six months as required by section 503B(b )(2)(A).

5Labeling and packaging

The containers of your outsourcing facility's drug products do not include information required by section 503B(a)(10)(B).

6Aseptic processing and sterility assurance

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.

7Aseptic processing and sterility assurance

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

8Aseptic processing and sterility assurance

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

9Laboratory and QC controls

Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications prior to release.

About this record

Extracted automatically from the document US FDA published on 2024-01-17. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

OPS International Incorporated D/B/A Olympia Pharmacy company profile — full history US FDA documents, 2024 Go to Findings search